These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16625656)

  • 21. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer-aided design of dry powder inhalers using computational fluid dynamics to assess performance.
    Suwandecha T; Wongpoowarak W; Srichana T
    Pharm Dev Technol; 2016; 21(1):54-60. PubMed ID: 25265389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure.
    Leung CMS; Tong Z; Zhou QT; Chan JGY; Tang P; Sun S; Yang R; Chan HK
    AAPS J; 2016 Sep; 18(5):1159-1167. PubMed ID: 27161214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems.
    Wong W; Fletcher DF; Traini D; Chan HK; Crapper J; Young PM
    J Pharm Sci; 2011 Jul; 100(7):2744-54. PubMed ID: 21360707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Apparatus to Deliver Mannitol Powder for Bronchial Provocation in Children Under Six Years Old.
    Tang P; Leung SS; Hor E; Ruzycki CA; Carrigy NB; Finlay WH; Brannan JD; Devadason S; Anderson SD; Sly PD; Samnick K; Chan HK
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):452-61. PubMed ID: 25844950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of an impinging jet for dispersion of dry powder inhalation aerosols.
    Wang Z; Lange CF; Finlay WH
    Int J Pharm; 2004 May; 275(1-2):123-31. PubMed ID: 15081143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring Bipolar Charge and Mass Distributions of Powder Aerosols by a Novel Tool (BOLAR).
    Wong J; Lin YW; Kwok PC; Niemelä V; Crapper J; Chan HK
    Mol Pharm; 2015 Sep; 12(9):3433-40. PubMed ID: 26222019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of particle properties in pharmaceutical powder inhalation formulations.
    Chew NY; Chan HK
    J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of computational fluid dynamics in inhaler design.
    Ruzycki CA; Javaheri E; Finlay WH
    Expert Opin Drug Deliv; 2013 Mar; 10(3):307-23. PubMed ID: 23289401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carrier particle emission and dispersion in transient CFD-DEM simulations of a capsule-based DPI.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2022 Jan; 168():106073. PubMed ID: 34774996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.
    de Boer AH; Hagedoorn P; Westerman EM; Le Brun PP; Heijerman HG; Frijlink HW
    Eur J Pharm Sci; 2006 Jun; 28(3):171-8. PubMed ID: 16650739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders.
    Chew NY; Bagster DF; Chan HK
    Int J Pharm; 2000 Sep; 206(1-2):75-83. PubMed ID: 11058812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novolizer: the new technology for the management of asthma therapy.
    Köhler D
    Curr Opin Pulm Med; 2003 Apr; 9 Suppl 1():S11-6. PubMed ID: 12974537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capsule-Based dry powder inhaler evaluation using CFD-DEM simulations and next generation impactor data.
    Almeida LC; Bharadwaj R; Eliahu A; Wassgren CR; Nagapudi K; Muliadi AR
    Eur J Pharm Sci; 2022 Aug; 175():106226. PubMed ID: 35643378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.